Biogen News and Research

RSS

Biogen Idec first quarter revenues increase 9% to $1.2 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing and commercialization of innovative therapies, today announced its first quarter 2011 results.

21 Apr 2011

FDA approves Rituxan-corticosteroid combination for Wegener's Granulomatosis and Microscopic Polyangiitis

Genentech, a member of the Roche Group and Biogen Idec announced today that the U.S. Food and Drug Administration (FDA) approved Rituxan® (rituximab), in combination with corticosteroids, as a new medicine for adults with Wegener's Granulomatosis (WG) and Microscopic Polyangiitis (MPA).

20 Apr 2011

EMA CHMP grants positive opinion for Biogen Idec's AVONEX PEN

Biogen Idec announced today that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of AVONEX® PEN™ for patients with relapsing multiple sclerosis (MS) and patients with a single demyelinating event.

19 Apr 2011

CHMP adopts EU positive opinion for TYSABRI labeling with anti-JCV antibody status

Biogen Idec and Elan Corporation, plc today announced that the Committee for Medicinal Products for Human Use has adopted a positive opinion for inclusion of an additional risk factor, anti-JC virus (JCV) antibody status, to the product label for TYSABRI in the European Union.

18 Apr 2011

Positive top-line results from Biogen BG-12 Phase 3 trial in RRMS

Biogen Idec announced today positive top-line results from DEFINE, the first of two pivotal Phase 3 clinical trials designed to evaluate the investigational oral compound BG-12 as a monotherapy in people with relapsing-remitting multiple sclerosis.

11 Apr 2011

Anergis SA closes funding round for allergy vaccines

Anergis SA announced today that it has closed a Series A financing round raising CHF 18 millions from European biotech funds and private local investors.

28 Mar 2011

Study to identify drug targets for rheumatoid arthritis patients not responding to anti-TNF therapies

GNS Healthcare, Inc., (GNS) the leading healthcare analytics company focused on enabling personalized medicine to improve human health, today announced the publication of results from a study focused on identifying novel drug targets for the one-third of rheumatoid arthritis patients who do not respond to leading anti-TNF therapies.

11 Mar 2011

EHSI to sign definitive agreement with OceanBASIS

Emerging Healthcare Solutions, Inc. announced today that it is moving forward with negotiations toward a profit participation agreement with OceanBASIS, a German company specializing in stem-cell and marine-collagen technologies and products.

11 Mar 2011

Santarus commences SAN-300 Phase I clinical study to treat inflammatory diseases

Santarus, Inc., a specialty biopharmaceutical company, today announced that it has initiated a Phase I clinical study with SAN-300, its anti-VLA-1 antibody.

10 Mar 2011

Acorda reports fourth quarter net revenue of $133.1 million for full year ended December 31, 2010

Acorda Therapeutics, Inc. today announced its financial results for the fourth quarter and full year ended December 31, 2010.

17 Feb 2011

Elan 2010 total revenue increases 5% to $1,169.7 million

Elan Corporation, plc today reported its fourth quarter and full-year 2010 financial results and provided financial guidance for 2011.

8 Feb 2011

Biogen Idec 2010 total revenues increase 8% to $4.7 billion

Biogen Idec Inc., a global biotechnology leader in the discovery, development, manufacturing, and commercialization of innovative therapies, today announced its full year and fourth quarter 2010 results.

1 Feb 2011

Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma

Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.

28 Jan 2011

EMA CHMP issues negative opinion against Biogen Idec's FAMPYRA for multiple sclerosis

Biogen Idec announced today that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a negative opinion recommending against approval of FAMPYRA to improve walking ability in adult patients with multiple sclerosis (MS) in the European Union. Biogen Idec intends to appeal this opinion and request a re-examination of the decision by the CHMP.

21 Jan 2011

Aegis releases Discoverant 4.0 manufacturing intelligence software

Aegis Analytical Corp., the leading provider of Enterprise Manufacturing and Process Intelligence software, announced today the availability of Aegis Discoverant® 4.0, the latest version of its global software platform.

18 Jan 2011

Biogen Idec, Elan propose updated product labeling for TYSABRI to FDA and EMA

Biogen Idec and Elan Corporation, plc announced that the companies have submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMA) to request review and approval to update the respective TYSABRI Prescribing Information and Summary of Product Characteristics.

22 Dec 2010

Biogen Idec acquires Neurimmune subsidiary

Biogen Idec and Neurimmune Holding AG today announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three central nervous system (CNS) targets: alpha-synuclein, tau and TDP-43.

21 Dec 2010

Exciting progress made in MS research during 2010

Exciting advances were made in 2010 in virtually every field of MS research. Progress toward finding new therapies for MS is illustrated by the availability of the first oral disease-modifying therapy for MS. Progress was also made toward finding ways to restore function and improving quality of life and specific MS symptoms through exercise, meditation, rehabilitation and medications, including the first therapy specifically approved to treat a symptom of MS (Ampyra).

20 Dec 2010

Novartis' Gilenya uptake to increase

A study published this week by ITG revealed that Novartis recently approved drug, Gilenya, has already taken share from market leaders in the multiple sclerosis (MS) market, and uptake is expected to increase significantly over the next year. Gilenya came onto the market in late September as the first FDA-approved oral disease-modifying MS drug, and Novartis initially faced safety concerns and monitoring requirements that deterred some physicians from adopting the new drug.

20 Dec 2010

Celebrity chef, registered dietitian team up to create nutrition program for people with MS

Amanda Freitag, celebrity chef and recurring judge on the Food Network's "Chopped," and Julie Barto, a registered dietitian specializing in multiple sclerosis, have teamed up to create a nutrition program especially for people with MS.

17 Dec 2010